HEALWELL AI and WELL Health Launch WELLTRUST Patient Consent Platform for Clinical Trials

HEALWELL AI Inc. and WELL Health Technologies Corp. have jointly launched the first phase of WELLTRUST, a platform enabling secure, consent-driven patient identification for clinical research within WELL-operated clinics in Canada. The platform addresses a critical bottleneck in clinical research by accelerating patient recruitment through a consent-first framework.

WELLTRUST accelerates clinical research recruitment by enabling patients interested in clinical trials and research to consent to future outreach. The potential scale is substantial, drawing on WELL Health's network of more than 240 clinics and over 43,000 healthcare providers across the United States and Canada. Patients who are not interested in participating in WELLTRUST can safely and securely decline participation and continue receiving care at WELL clinics as they had before.

The core of the WELLTRUST platform is its foundational "consent-first" principle. Patients receiving care at WELL-operated clinics in Canada can voluntarily opt-in to be contacted regarding potential clinical trial participation. Those who decline will continue to receive standard care without any alteration to their treatment. WELLTRUST enables patients to clearly and confidently consent to their personal health information being used for specific purposes, including providing consent to be contacted about clinical trials and participation in information review studies.

The first commercial application of WELLTRUST leverages HEALWELL's DARWEN AI platform to accelerate the identification and engagement of high-fit patients with chronic or complex conditions who have explicitly consented to be contacted about clinical trial opportunities. This technology screens the pool of consenting patients to precisely identify individuals with chronic, rare, or complex diseases who may qualify for specific research protocols.

The platform includes a unified privacy, consent, and data-governance layer to meet Canadian privacy and regulatory standards, enabling compliant partnerships with pharmaceutical sponsors, research organizations, and clinical trial networks. WELLTRUST provides patients with clear, flexible, and revocable control over consent, while enabling researchers and clinicians to identify appropriate patients in an ethical, privacy-first way.

WELLTRUST is designed to support additional use cases as it grows, including real-world evidence generation and enhanced clinical decision support tools. The platform launch follows a series of internal integration steps previously outlined by HEALWELL in a corporate update dated February 12. The company consolidated AI capabilities from its Khure and Pentavere acquisitions into a unified DARWEN-based engine. It also merged its operational and sales teams and expanded cross-selling through coordinated Orion-Verosource initiatives.

The same update detailed HEALWELL's broader timeline. The North American launch of Amadeus AI, a digital, AI-powered patient health record system, is scheduled for the first half of 2026, with international expansion to follow by late 2026. Furthermore, HEALWELL is evaluating a strategic investment vehicle exceeding $2 million USD that holds a stake in xAI. The update noted that xAI merged with SpaceX on February 2, 2026.

Despite these operational developments, HEALWELL AI's shares continue to face selling pressure. The stock closed at €0.39 on Friday, hovering near its 52-week low. The company's full-year financial results are anticipated by late March 2026.